» Articles » PMID: 23608464

Oxidative Stress and Increased Formation of Vasoconstricting F2-isoprostanes in Patients with Reversible Cerebral Vasoconstriction Syndrome

Overview
Date 2013 Apr 24
PMID 23608464
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The pathophysiology of reversible cerebral vasoconstriction syndrome (RCVS) is unknown. Oxidative stress is detrimental to endothelial function and vascular reactivity. We hypothesized that the oxidative stress marker 8-iso-prostaglandin F2α, which is also a potent vasoconstrictor, might contribute to the pathogenesis of RCVS. Recruited participants included 103RCVS patients, 53 patients with primary headache with acute severe attacks, and 54 healthy controls. Subjects recruited prior to 2009 were discovery cohort, whereas those after 2009, replication cohort. Urine samples were obtained from all patients at registration and from 79 patients with RCVS again at remission stage. Urine 8-iso-prostaglandin F2α was analyzed by liquid chromatography-tandem mass spectrometry. Patients with RCVS received magnetic resonance angiography and transcranial color-coded sonography. In RCVS patients, the urine 8-iso-prostaglandin F2α level was higher than that in the other groups in discovery, replication, and combined cohorts (RCVS, 0.29±0.18; primary headache with acute severe attacks, 0.21±0.19; control, 0.18±0.09ng/mg creatinine; P<0.001), and it was positively correlated with the flow velocities of major intracranial arteries, especially within the first week of disease onset (middle cerebral artery, Spearman's correlation coefficient [rs]=0.580, P=0.002; anterior cerebral artery, rs=0.472, P=0.042; posterior cerebral artery, rs=0.457, P=0.022; basilar artery, rs= 0.530, P=0.002). The 8-iso-prostaglandin F2α level decreased from the ictalto remission stage in RCVS patients (0.31±0.21 vs 0.16±0.10ng/mg creatinine, P<0.001). 8-Iso-prostaglandin F2α was higher in patients with RCVS and correlated with the severity of vasoconstrictions. Further studies are required to explore its potential pathogenic role.

Citing Articles

Treatment-Related Reversible Cerebral Vasoconstriction Syndrome.

Avola G, Pezzini A J Clin Med. 2024; 13(19).

PMID: 39407990 PMC: 11478140. DOI: 10.3390/jcm13195930.


Dynamic changes in glymphatic function in reversible cerebral vasoconstriction syndrome.

Wu C, Kuo Y, Ling Y, Wang Y, Fuh J, Lirng J J Headache Pain. 2024; 25(1):17.

PMID: 38317074 PMC: 10840154. DOI: 10.1186/s10194-024-01726-1.


Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis.

Bonura A, Iaccarino G, Rossi S, Capone F, Motolese F, Calandrelli R J Neurol. 2023; 270(6):2826-2852.

PMID: 37014421 PMC: 10071475. DOI: 10.1007/s00415-023-11684-4.


Pathophysiology of reversible cerebral vasoconstriction syndrome.

Chen S, Wang S J Biomed Sci. 2022; 29(1):72.

PMID: 36127720 PMC: 9489486. DOI: 10.1186/s12929-022-00857-4.


Postpartum reversible cerebral vasoconstriction with cortical subarachnoid hemorrhage and posterior reversible encephalopathy syndrome concomitant with vertebral artery dissection diagnosed by MRI MSDE method: A case report and review of literature.

Sano K, Kuge A, Kondo R, Yamaki T, Homma H, Saito S Clin Case Rep. 2022; 10(9):e6257.

PMID: 36110331 PMC: 9465692. DOI: 10.1002/ccr3.6257.